

Appendix 1 (part 1 of 2). Preprinted order for venous thromboembolism prophylaxis, developed and used by the Burnaby Hospital.
 © 2010 Burnaby Hospital. Reproduced by permission.

IF YOU RECEIVED THIS FACSIMILE IN ERROR, PLEASE CALL 604-806-8886 IMMEDIATELY



PRESCRIBER'S ORDERS

NO DRUG WILL BE DISPENSED OR ADMINISTERED
 WITHOUT A COMPLETED
CAUTION SHEET
 ALLERGY/INTOLERANCE STATUS FORM (PHC-PH047)

DATE AND TIME	VTE RISK ASSESSMENT AND PROPHYLAXIS ORDERS (REGIONAL) <small>(items with check boxes must be selected to be ordered)</small>
	Page 1 of 1
	Patient Weight: _____ kg Platelet count: _____ x 10 ⁹ /L on (Date): _____ <div style="border: 1px solid black; padding: 2px; margin: 5px auto; width: fit-content;"> Refer to VTE Risk Assessment And Thromboprophylaxis Recommendations on reverse </div> <p>RISK ASSESSMENT:</p> <input type="checkbox"/> Low risk: Early ambulation; no anticoagulant or mechanical prophylaxis <input type="checkbox"/> Moderate or High risk; order anticoagulant prophylaxis unless contraindicated (indicate reason below): _____ <p>Contraindications to anticoagulant prophylaxis:</p> <input type="checkbox"/> Active bleeding of clinical significance requiring intervention <input type="checkbox"/> High risk of serious bleeding or bleeding into a critical site (e.g. intracranial, intraspinal, pericardial, intraocular, retroperitoneal, intra-articular) <input type="checkbox"/> Known major bleeding disorder or acquired coagulopathy (consider Hematology consult) <input type="checkbox"/> Platelet count less than 50 x 10 ⁹ /L (consider Hematology consult) <input type="checkbox"/> History of heparin-induced thrombocytopenia (HIT) see Footnotes and Precaution 7 on reverse <input type="checkbox"/> Patient already receiving therapeutic anticoagulation Other contraindication (specify): _____ Reassess daily to start anticoagulant prophylaxis when contraindication resolves <p>ANTICOAGULANT PROPHYLAXIS: see Footnotes and Precautions 6 to 9 on reverse</p> Give first post-op dose at (time): _____ on (date): _____ <input type="checkbox"/> dalteparin 5000 units subcutaneous daily at 18:00 until discharge *OR* <input type="checkbox"/> for patients with severe renal impairment, heparin 5000 units subcutaneous Q12H until discharge *OR* Other: _____ Reason: _____ Monitor patients with epidural catheter receiving anticoagulant prophylaxis for symptoms and signs of spinal hematoma <div style="border: 1px solid black; padding: 5px; margin: 5px auto; width: fit-content;"> Epidural catheter should not be removed within 12 hours of a dose of dalteparin or heparin After epidural catheter removal, dalteparin or heparin should not be given for at least 2 hours </div> <p>MECHANICAL PROPHYLAXIS: (only when anticoagulant prophylaxis contraindicated)</p> <input type="checkbox"/> Sequential compression device (SCD) <input type="checkbox"/> Mechanical prophylaxis contraindicated (see back for list of contraindications) Apply to lower limb(s) continuously until anticoagulant prophylaxis starts or discharge Interrupt for skin care, assessments, toileting and ambulation only
	_____ Printed Name _____ Signature _____ College ID _____ Pager

EPHCPH408 ALL NEW ORDERS MUST BE FLAGGED
 Form No. PHC-PH408 (R. Dec 15-11) FAX COMPLETED ORDERS TO PHARMACY PLACE ORIGINAL IN PATIENT'S CHART

Supplemental material for Rafizadeh R, Turgeon RD, Batterink J, Su V, Lau A. Characterization of venous thromboembolism risk in medical inpatients using different clinical risk assessment models. *Can J Hosp Pharm.* 2016;69(6):454-9.

Appendix 1 (part 2 of 2). Preprinted order for venous thromboembolism prophylaxis, developed and used by the Burnaby Hospital.
 © 2010 Burnaby Hospital. Reproduced by permission.

VTE RISK ASSESSMENT AND THROMBOPROPHYLAXIS RECOMMENDATION													
Patient Risk Groups (satisfaction of any one or more of the listed criteria)	Thromboprophylaxis Recommended												
Low Risk Group <ul style="list-style-type: none"> Day surgery¹ without any VTE risk factors (see below) No reduction in mobility compared to usual state Surgical procedure with a total anesthetic and surgical time of less than 60 minutes with no risk factors for VTE (see below) 	Early ambulation												
Moderate or High Risk Group <ul style="list-style-type: none"> Any medical or surgical patient having had or are expected to have significantly reduced mobility for 3 days or more²⁻⁹ Medical patients with ongoing reduced mobility (compared to their usual state) AND have one or more risk factors for VTE (see below)^{2,7-9} Surgical procedure with a total anesthetic and surgical time of 60 minutes or longer³⁻⁶ Acute surgical admission with an inflammatory or intra-abdominal condition³⁻⁶ Surgical patients with one or more risk factors for VTE (see below)³⁻⁵ 	LMWH (heparin if GFR less than 10 mL/min) ⁴⁻⁹												
Obstetrical Patients with Increased Risk <ul style="list-style-type: none"> Having one or more risk factors for VTE (see below) Pregnancy-related risk factors: <ul style="list-style-type: none"> Ovarian hyperstimulation Hyperemesis gravidarum Multiple pregnancy Preeclampsia Emergency caesarean section 	Consider LMWH (heparin if GFR less than 10 mL/min) ⁴⁻⁹												
RISK FACTORS FOR VTE													
<ul style="list-style-type: none"> Age 60 years or over Active cancer and cancer treatment Previous VTE Critical Care admission Obesity (BMI more than 30 kg/m²) Known thrombophilia First degree relative with VTE Varicose veins with phlebitis Estrogen-containing oral contraception Hormone replacement therapy 	One or more significant medical conditions: <ul style="list-style-type: none"> Sepsis or severe acute infection Heart disease (eg. CHF) Respiratory pathology (eg. COPD) Inflammatory condition (eg. inflammatory bowel disease) Rheumatological disease Nephrotic syndrome Antiphospholipid syndrome 												
CONTRAINDICATIONS FOR MECHANICAL PROPHYLAXIS													
<ul style="list-style-type: none"> Acute stroke with immobility (unable to walk independently to the toilet) Peripheral vascular disease with absent pedal pulses Severe peripheral neuropathy Skin breakdown, ulcers, gangrene, cellulitis, or dermatitis Skin grafting within last 3 months Allergy to stocking or compression cuff materials Unable to size or apply properly due to deformity, recent surgery or trauma 													
FOOTNOTES AND PRECAUTIONS													
<ol style="list-style-type: none"> Day surgery includes patients admitted and discharged within 24 hours for an elective surgical or invasive procedure. In medical patients receiving anticoagulant prophylaxis, the NNT to prevent symptomatic DVT is 212 and non-fatal PE is 300; the NNH for major bleed is 430. There is no evidence for mechanical thromboprophylaxis in medical patients. In surgical patients receiving anticoagulant prophylaxis, the NNT to prevent symptomatic DVT is 20 to 106 and non-fatal PE is 110 to 150; the NNH for major bleed is 70 to 100. There is weak evidence for using mechanical thromboprophylaxis alone and weaker evidence for combining anticoagulant and mechanical prophylaxis to improve efficacy. First post-op dose of LMWH should be given after hemostasis is achieved and as soon as it is safe to do so (usually 12 to 24 hr after surgery). This should take into account the risks of bleeding, thrombosis and timing of subsequent surgery if needed. Prophylaxis for up to 30 days after surgery is recommended in those having hip replacement, hip fracture surgery, abdominal or pelvic surgery for cancer, and those with multiple risk factors. Heparin 5000 units subcut BID should be used if patient is awaiting urgent surgery and is a candidate for neuroaxial blockade. Refer to Peri-operative Pain Service or Anesthesia regarding timing of epidural catheter insertion and removal. Dalteparin and heparin should not be given in patients with heparin induced thrombocytopenia. Consider consulting Hematology regarding the use of alternative agents (e.g. fondaparinux or argatroban). If eGFR is 10 to 30 mL/min and duration of prophylaxis exceeds 10 days, can consider using heparin 5000 units subcut BID. If eGFR less than 10 mL/min or dialysis dependent use heparin 5000 units BID. If patient's weight is over 100 kg, consider increasing dose of dalteparin to 5000 units BID or heparin 5000 units TID. 													
<table border="1"> <thead> <tr> <th>Weight range</th> <th>dalteparin (if eGFR 10 mL/min or above)</th> <th>heparin (if eGFR less than 10 mL/min)</th> </tr> </thead> <tbody> <tr> <td>40 kg or less</td> <td>2500 units subcutaneous once daily</td> <td>2500 units subcutaneous Q12H</td> </tr> <tr> <td>41 kg to 100 kg</td> <td>5000 units subcutaneous once daily</td> <td>5000 units subcutaneous Q12H</td> </tr> <tr> <td>Over 100 kg</td> <td>5000 units subcutaneous Q12H</td> <td>5000 units subcutaneous Q8H</td> </tr> </tbody> </table>		Weight range	dalteparin (if eGFR 10 mL/min or above)	heparin (if eGFR less than 10 mL/min)	40 kg or less	2500 units subcutaneous once daily	2500 units subcutaneous Q12H	41 kg to 100 kg	5000 units subcutaneous once daily	5000 units subcutaneous Q12H	Over 100 kg	5000 units subcutaneous Q12H	5000 units subcutaneous Q8H
Weight range	dalteparin (if eGFR 10 mL/min or above)	heparin (if eGFR less than 10 mL/min)											
40 kg or less	2500 units subcutaneous once daily	2500 units subcutaneous Q12H											
41 kg to 100 kg	5000 units subcutaneous once daily	5000 units subcutaneous Q12H											
Over 100 kg	5000 units subcutaneous Q12H	5000 units subcutaneous Q8H											

Form No. PHC-PH408 (R. Dec 15-11)

BACK

Supplemental material for Rafizadeh R, Turgeon RD, Batterink J, Su V, Lau A. Characterization of venous thromboembolism risk in medical inpatients using different clinical risk assessment models. *Can J Hosp Pharm.* 2016;69(6):454-9.